American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients
July 13, 2021 08:30 ET
|
Daxor Corporation
Cites Evidence from Studies Utilizing Daxor’s BVA-100® Blood Volume Analyzer NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume...
Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
March 30, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for the...
MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
March 08, 2018 16:02 ET
|
MyoKardia, Inc.
Met Primary Endpoint and Key Secondary Endpoints with Statistical Significance Study Results Inform Phase 3 EXPLORER-HCM Dosing; First Patient Planned for Q2 2018 Conference Call Today...
![On-X Life Technologies Inc. logo](/news-release/logo/214172/0/214172.jpg?lastModified=12%2F10%2F2016%2002%3A11%3A14&size=2)
Predicting Long-Term Costs of Heart Valve Replacement Study to be Presented at American College of Cardiology Meeting
March 08, 2013 08:00 ET
|
On-X Life Technologies Inc.
AUSTIN, Texas, March 8, 2013 (GLOBE NEWSWIRE) -- On-X® Life Technologies, Inc. (On-X LTI) announced today that a cost analysis entitled, "Predicting Long-Term Costs of Heart Valve Replacement: A...
![On-X Life Technologies Inc. logo](/news-release/logo/214172/0/214172.jpg?lastModified=12%2F10%2F2016%2002%3A11%3A14&size=2)
On-X Life Technologies Submits for FDA/CE Approval of Reduced Anticoagulation Indication for On-X Aortic Heart Valve
October 22, 2012 08:01 ET
|
On-X Life Technologies Inc.
If approval is received, the On-X valve will become the first aortic valve that allows patients to be maintained at levels of anticoagulation below currently recommended professional society...